SAN

83.15

+0.18%↑

UCB

264.7

+3.56%↑

SHL.DE

36.22

+1.03%↑

ARGX

637.2

+3.14%↑

VIE

33.24

+1.22%↑

SAN

83.15

+0.18%↑

UCB

264.7

+3.56%↑

SHL.DE

36.22

+1.03%↑

ARGX

637.2

+3.14%↑

VIE

33.24

+1.22%↑

SAN

83.15

+0.18%↑

UCB

264.7

+3.56%↑

SHL.DE

36.22

+1.03%↑

ARGX

637.2

+3.14%↑

VIE

33.24

+1.22%↑

SAN

83.15

+0.18%↑

UCB

264.7

+3.56%↑

SHL.DE

36.22

+1.03%↑

ARGX

637.2

+3.14%↑

VIE

33.24

+1.22%↑

SAN

83.15

+0.18%↑

UCB

264.7

+3.56%↑

SHL.DE

36.22

+1.03%↑

ARGX

637.2

+3.14%↑

VIE

33.24

+1.22%↑

Search

Imerys SA.

Deschisă

SectorSănătate

21.24 -1.3

Rezumat

Modificarea prețului

24h

Curent

Minim

21.22

Maxim

21.8

Indicatori cheie

By Trading Economics

Venit

-550M

-479M

Vânzări

-130M

1.6B

P/E

Medie Sector

12.55

56.063

Randament dividend

3.55

Marjă de profit

-29.457

Angajați

14,878

EBITDA

-310M

-43M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+30.68% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.55%

2.45%

Următoarele câștiguri

27 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-371M

1.8B

Deschiderea anterioară

22.54

Închiderea anterioară

21.24

Sentimentul știrilor

By Acuity

15%

85%

25 / 349 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Imerys SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Nike, RH, NCino

31 mar. 2026, 22:35 UTC

Câștiguri

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr. 2026, 00:00 UTC

Achiziții, Fuziuni, Preluări

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar. 2026, 23:50 UTC

Achiziții, Fuziuni, Preluări

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar. 2026, 23:21 UTC

Câștiguri

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar. 2026, 23:14 UTC

Market Talk
Câștiguri

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar. 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss Widens >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar. 2026, 21:46 UTC

Achiziții, Fuziuni, Preluări

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar. 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar. 2026, 21:33 UTC

Achiziții, Fuziuni, Preluări

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar. 2026, 21:33 UTC

Câștiguri

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar. 2026, 21:32 UTC

Câștiguri

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar. 2026, 21:28 UTC

Câștiguri

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar. 2026, 21:26 UTC

Câștiguri

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar. 2026, 21:25 UTC

Câștiguri

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar. 2026, 21:24 UTC

Market Talk
Câștiguri

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar. 2026, 21:22 UTC

Câștiguri

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar. 2026, 21:22 UTC

Câștiguri

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar. 2026, 21:21 UTC

Câștiguri

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar. 2026, 21:20 UTC

Câștiguri

Nike CEO: Converse Remains Important to Portfolio

Comparație

Modificare preț

Imerys SA. Așteptări

Obiectiv de preț

By TipRanks

30.68% sus

Prognoză pe 12 luni

Medie 27.6 EUR  30.68%

Maxim 32.2 EUR

Minim 23 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImerys SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

29.06 / 30.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

25 / 349 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Imerys SA.

Imerys S.A. provides mineral-based specialty solutions for various industries worldwide. The company provides additives for paints, coatings, adhesives, caulks, sealants, and rubber; minerals for technical ceramics and traditional ceramics; functional additives for plastics and thermoset; high-performance binders for dry mix mortars and floor screeds; fillers and coatings for paper, board, and packaging applications; filtration agents for liquids and blood plasma; pharmaceutical diluents, coloring agents, processing aids, glidants, and lubricants for tablet production; engineered minerals for cosmetic industry; food additives to preserve flavor; coating agents to improve fertilizer fow; mineral-based cat litters; alumina for high-performance abrasives and graphite in brake pads; and carbon black for conductivity in onboard data systems. The company also offers minerals used to produce high purity silicon metal for electronics and solar panels; graphite and carbon-based solutions for industrial applications; mineral solutions for batteries and energy storage; refractory minerals and solutions for high-temperature processes; and alumina and zirconia for abrasives. It serves construction and infrastructure, consumer and health care, automotive and transportation, energy and electronics, and industry and equipment industries. The company was incorporated in 1880 and is headquartered in Paris, France. The company is a subsidiary of Belgian Securities BV.
help-icon Live chat